Cantor Fitzgerald Forecasts MREO FY2025 Earnings

Mereo BioPharma Group plc (NASDAQ:MREO) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Mereo BioPharma Group in a report issued on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings of ($0.08) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $7.00 price target on the stock. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share.

Mereo BioPharma Group (NASDAQ:MREO) last issued its earnings results on Wednesday, March 26th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.03).

A number of other research firms have also issued reports on MREO. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 target price on shares of Mereo BioPharma Group in a report on Wednesday, March 26th. JPMorgan Chase & Co. assumed coverage on Mereo BioPharma Group in a research note on Thursday. They set an “overweight” rating and a $7.00 price objective for the company. Jefferies Financial Group assumed coverage on Mereo BioPharma Group in a research report on Friday, December 6th. They issued a “buy” rating and a $7.00 price target for the company. Finally, Lifesci Capital began coverage on shares of Mereo BioPharma Group in a research note on Tuesday, December 24th. They set an “outperform” rating and a $10.00 price objective for the company. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $7.71.

Mereo BioPharma Group Trading Down 4.6 %

MREO stock opened at $2.30 on Monday. The company has a market capitalization of $356.84 million, a P/E ratio of -38.33 and a beta of 1.03. The firm has a 50 day simple moving average of $2.72 and a 200-day simple moving average of $3.48. Mereo BioPharma Group has a twelve month low of $2.22 and a twelve month high of $5.02.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MREO. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Mereo BioPharma Group during the fourth quarter worth $3,377,000. Woodline Partners LP bought a new position in Mereo BioPharma Group in the fourth quarter valued at about $2,166,000. Tema Etfs LLC bought a new position in Mereo BioPharma Group in the fourth quarter valued at about $3,117,000. Janus Henderson Group PLC boosted its stake in shares of Mereo BioPharma Group by 38.7% during the fourth quarter. Janus Henderson Group PLC now owns 17,122,563 shares of the company’s stock valued at $59,843,000 after purchasing an additional 4,776,697 shares in the last quarter. Finally, Graham Capital Management L.P. increased its stake in shares of Mereo BioPharma Group by 74.7% in the fourth quarter. Graham Capital Management L.P. now owns 22,189 shares of the company’s stock valued at $78,000 after buying an additional 9,490 shares during the period. 62.83% of the stock is currently owned by institutional investors and hedge funds.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.